MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-021-01033-1

Медицинская библиотека · Journal of hematology & oncology · 2021

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).

Shi Yuankai, Wu Jianqiu, Wang Zhen, Zhang Liling, Wang Zhao, Zhang Mingzhi, Cen Hong, Peng Zhigang, Li Yufu, Fan Lei, Guo Ye, Ma Liping, Cui Jie, Gao Yuhuan, Yang Haiyan, Zhang Hongyu, Wang Lin, Zhang Weihua, Zhang Huilai, Xie Liping, Jiang Ming, Zhou Hui, Shuang Yuerong, Su Hang, Ke Xiaoyan, Jin Chuan, Du Xin, Du Xin, Liu Li, Xi Yaming, Ge Zheng, Feng Ru, Zhang Yang, Zhou Shengyu, Xie Fan, Wang Qian

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety of geptanolimab (GB226), an anti-PD-1 antibody, in r/r PTCL patients.

METHODS

We did this single-arm, multicenter phase 2 study across 41 sites in China. Eligible patients with r/r PTCL received geptanolimab 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity. All patients who received at least one dose of geptanolimab and histological confirmed PTCL entered full analysis set (FAS). The primary endpoint was objective response rate (ORR) in FAS assessed by the independent radiological review committee (IRRC) per Lugano 2014 criteria.

RESULTS

Between July 12, 2018, and August 15, 2019, 102 patients were enrolled and received at least one dose of geptanolimab. At the data cutoff date (August 15, 2020), the median follow-up was 4.06 (range 0.30-22.9) months. For 89 patients in FAS, 36 achieved objective response (40.4%, 95% CI 30.2-51.4), of which 13 (14.6%) were complete response and 23 (25.8%) had partial response assessed by IRRC. The median duration of response (DOR) was 11.4 (95% CI 4.8 to not reached) months per IRRC. Patients with PD-L1 expression ≥ 50% derived more benefit from geptanolimab treatment compared to < 50% ones (ORR, 53.3% vs. 25.0%, p = 0.013; median PFS 6.2 vs. 1.5 months, p = 0.002). Grade ≥ 3 treatment-related adverse events occurred in 26 (25.5%) patients, and the most commonly observed were lymphocyte count decreased (n = 4) and platelet count decreased (n = 3). Serious adverse events were observed in 45 (44.1%) patients and 19 (18.6%) were treatment related.

CONCLUSIONS

In this study, geptanolimab showed promising activity and manageable safety profile in patients with r/r PTCL. Anti-PD-1 antibody could be a new treatment approach for this patient population.

TRIAL REGISTRATION: This clinical trial was registered at the ClinicalTrials.gov (NCT03502629) on April 18, 2018.

Для цитирования: Shi Yuankai, Wu Jianqiu, Wang Zhen, Zhang Liling, Wang Zhao, Zhang Mingzhi, Cen Hong, Peng Zhigang, Li Yufu, Fan Lei, Guo Ye, Ma Liping, Cui Jie, Gao Yuhuan, Yang Haiyan, Zhang Hongyu, Wang Lin, Zhang Weihua, Zhang Huilai, Xie Liping, Jiang Ming, Zhou Hui, Shuang Yuerong, Su Hang, Ke Xiaoyan, Jin Chuan, Du Xin, Du Xin, Liu Li, Xi Yaming, Ge Zheng, Feng Ru, Zhang Yang, Zhou Shengyu, Xie Fan, Wang Qian. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).. Journal of hematology & oncology. 2021. DOI: 10.1186/s13045-021-01033-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.